How AAV immuno-gene therapy works
We deliver vectorized, engineered cytokines directly to the tumor.
Our low-dosed gene therapy is precisely infused directly into the tumor, avoiding healthy cells.
Endogenous targeted cytokine expression rapidly kills tumor cells.
Our therapy destroys tumor cells in both resected and unresected tumors, including lingering tumor cells that are the primary culprit for recurrence in many cancers.
Cytokine expression supercharges the innate immune response.
Release of inflammatory cytokines from the infusion site activates the innate immune response by activating macrophages and recruiting natural killer cells.
Antigens can further activate the adaptive immune response.
Release of tumor and AAV capsid antigens from the dying tumor can activate an adaptive immune response by recruiting cytotoxic T lymphocytes.
Our approach is universal
This is the first AAV gene therapy that can be made once and used in numerous indications – a huge leap forward for the field.
Our universal design drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial.
Most importantly, ‘universal’ means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.
We redefine cytokine immunotherapy
Cytokines play a key role in recruiting and activating immune cells and are an ideal tool for immunotherapy.
But significant challenges have prevented cytokine immunotherapy from realizing its cancer-fighting potential … until Siren, that is.